Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring recurrent adult Hodgkin lymphoma, recurrent/refractory childhood Hodgkin lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed residual or relapsed Hodgkin's lymphoma following conventional dose standard chemotherapy Presence of the following prognostic factors are allowed: B symptoms (fever, weight loss, night sweats) Extranodal disease Complete remission of less than 1 year duration PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease No chronic active or persistent hepatitis Renal: No history of chronic renal insufficiency Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No myocardial infarction within the past 6 months No unstable angina No significant cardiac arrhythmias other than chronic atrial fibrillation Ejection fraction at least 50% Pulmonary: DLCO at least 50% Other: No uncontrolled infection HIV negative At least 5 years since prior malignancy except: Curatively treated cutaneous basal cell carcinoma Carcinoma in situ of the cervix Not pregnant or nursing Fertile women must use effective contraception PRIOR CONCURRENT THERAPY: Must have failed conventional dose standard chemotherapy
Sites / Locations
- Memorial Sloan-Kettering Cancer Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Arm I
Arm II
Arm III
(0-1 adverse prognostic factors): Patients receive ifosfamide by 24 hour infusion on day 2. Carboplatin is administered on day 2. Etoposide IV is administered once daily on days 1-3. Patients then receive filgrastim (G-CSF) subcutaneously or IV on days 5-12. Patients receive another course of ICE chemotherapy 2-3 weeks after the first course.
(2 adverse prognostic factors): Patients receive the first course of ICE as in Arm I
Arm III (3 adverse prognostic factors): Patients receive cyclophosphamide IV daily for 2 days, then G-CSF beginning on day 4 until blood stem cells are collected